ReviewFrontiers in cell and developmental biology2026
SPP1 (osteopontin): a key regulator orchestrating cancer progression and non-cancerous pathologies - therapeutic opportunities and future directions.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secreted Phosphoprotein 1 (SPP1) is a multifaceted matricellular glycoprotein that mediates diverse biological processes via integrin and CD44 receptor signaling. While its profound contributions to tumor progression and metastasis are extensively documented, emerging evidence underscores its pivotal roles across diverse non-cancerous conditions, including pregnancy-related complications, fibrotic diseases and neurological disorders. Crucially, SPP1 exhibits functional pleiotropy, orchestrating angiogenesis and epithelial-mesenchymal transition, while modulating immunosuppression. These collective actions drive disease progression, establishing SPP1 as a compelling therapeutic target. This review synthesizes current understanding of SPP1 biology, highlighting mechanistic insights imperative for translating its therapeutic potential into safe, precision-targeted interventions against diverse SPP1-driven pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.